Objective: To estimate the needed workforce of trained neurointerventionalists (NIs) to perform endovascular therapy (ET) for eligible patients with acute ischemic stroke (AIS).
with use of chemical fibrinolytics within 6 hours of symptom onset. 4, 5 Bridging therapy, following IV therapy with intra-arterial techniques, has proven its feasibility and safety and is being evaluated for efficacy in randomized prospective studies, the Interventional Management of Stroke (IMS III) trial and possibly the Trial and Cost Effectiveness Evaluation of Intra-arterial Thrombectomy in Acute Ischemic Stroke (THRACE) study. 6, 7 Penumbral imaging has shown that "imaging selected patients" would benefit from delayed revascularization up to 24 hours from onset of symptoms (imaging vs timing proponents). [8] [9] [10] [11] To achieve safe and effective delivery of endovascular therapy to AIS patients, an understanding of the availability of neurointerventionalists (NIs) and the demand for endovascular AIS therapy is important. The interrelationship between the supply of proficient NIs and the need for endovascular stroke therapy is complex. The highly specialized skills involved in AIS endovascular therapy demand a sufficient case volume to maintain skill level; however, this must be balanced against the risk of burnout from an overwhelming practice. Understanding the balance between neurointerventional availability and stroke demand is important for organized stroke system planning.
METHOD AND RESULTS Estimating the supply.
The supply is the number of NIs trained according to Accreditation Council for Graduate Medical Education guidelines (www. acgme.org/acWebsite/downloads/RRC_progReq/422_endovascu-lar_neuroradiology_01012008_u06102008.pdf, www.ACGME. org). Data on the number of NIs in the United States, number of centers performing endovascular intervention, and number of NI fellowship programs were obtained from Society of Neurointerventional Surgery (SNIS), Society of Vascular & Interventional Neurology (SVIN), Concentric Medical Inc., and Penumbra Inc. The number of fellowship-trained NIs, estimated as per 2011, is close to 800, according to SNIS senior and active member sources and SVIN active member sources. The trained NIs can be divided into approximately 600 neuroradiologists, 100 neurosurgeons, and 100 neurologists. In addition to the 800 practicing and trained NIs, at least every year there are close to 40 new NIs graduating across the country, which would make the number close to 1,000 in the next 5 years and close to 1,200 in the next 10 years.
Estimating the demand. The annual demand is defined as the proportion of AIS patients who would meet the inclusion criteria or clinical standards for endovascular therapy. This was estimated based on the following 3 methods. In the first method, a population-based approach was used by calculating the total number of all ischemic strokes in the United States from published annual incidence estimates by epidemiologic populationbased studies. Population and ischemic stroke incidence data were extracted with use of US census and Centers for Disease Control and Prevention data from 2009 estimates. 12 To estimate the number of acute AIS patients eligible for endovascular therapy, we estimated the number of large-vessel occlusions from population-based AIS subtypes. American Heart Association/ American Stroke Association stroke statistics and published data on stroke mortality were used to estimate the stroke incidence. [13] [14] [15] The second method was a clinical trial-based approach that relied on published prospective intra-arterial studies. This method was used to determine the proportion of patients enrolled from the number who were screened for endovascular AIS therapy trials. In the third method, a local and regional registry approach was used to estimate the number of AIS patients eligible for endovascular therapy, based on a single-center experience and regional published registries of admissions for AIS and the proportion of patients with severe stroke and largevessel disease.
Population-and epidemiology-based estimate.
There are approximately 795,000 strokes every year in the United States; of these, only 85% to 87% are ischemic (i.e., about 675,000 are AIS). [12] [13] [14] [15] Based on US census data, the estimated US population is 312 million, 12 and the incidence of all strokes (795,000/312 million) equals 0.26%. Estimating the number of ischemic strokes at 675,000 translates to an ischemic stroke annual incidence of 0.22% (figure, A). This number (0.22%) may be different if one considers the age-specific annual incidence of completed strokes from the Framingham Longitudinal Study. 16 The findings showed that 1.67 million of the population aged 35 to 94 years may have ischemic and hemorrhagic strokes, of which 0.85 or 1.42 million would have ischemic stroke; however, the group between 35 and 85 years of age constitutes 54% of the cases, or 766,800. This brings the number of first-ever strokes closer to the American Stroke Association estimate. The question is, of the population first-ever strokes, what is the proportion that may be eligible for endovascular therapy?
Estimating the number of AIS cases requiring intra-arterial therapy necessitates considerable assumptions about the prevalence of large-vessel disease and the proportion of patients who would meet the endovascular therapy inclusion criteria. The prevalence of large-vessel disease, including cardioembolic stroke, is 27%, according to a Northern Manhattan study. 16 Estimating 27% of 675,000 results in a projected 182,250 largevessel strokes. In our experience, the percentage of patients with severe stroke (NIH Stroke Scale [NIHSS] score greater than 8) is an estimated 35%, or about 63,788 (assuming one-third of these patients may meet all inclusion criteria for endovascular therapy, rather than the full 27%). This seems to be an overestimate. The population-and epidemiology-based AIS endovascular demand would be about 9% to 27% (assuming all large-vessel occlusions meet treatment criteria-less likely-from among the total 675,000 annual ischemic strokes, or ϳ60,750 to 182,250 patients annually).
Estimates based on prospective acute stroke endovascular treatment studies. Table 1 shows prior prospective studies that screened thousands of AIS patients to enroll only a small percentage into endovascular therapy, ranging between 2% and 16% (mean, 6.1%) of the screened patients. The data derived from these studies are limited by their mixed nature; some enrolled patients up to 3 hours from symptom onset (IMS I and II) and others up to 6 hours (PROACT I and II trials and MELT) or 8 hours (Mechanical Embolus Removal in Cerebral Ischemia [MERCI] Trial, Multi-MERCI, and Penumbra). 4 -7,17-20 Table 2 summarizes all the prospective studies. Based on the screening data from prospective intra-arterial chemical and mechanical thrombectomy trials, the mean percentage of patients who were treated from those who were screened is 6.1% Ϯ 4.6% (1.5% to 10.7%), or an annual volume of ϳ43,000 within a range of 11,000 to 75,000.
Estimates based on acute ischemic stroke registries. In a study of why patients are excluded from acute stroke intervention, only 2.4% underwent intra-arterial thrombolysis. The reasons for exclusion included TIA in 14% of patients and improving neurologic deficit in 10%. 21 In a recent study with use of a CT angiography database, 1,341 AIS patients underwent CT angiography on admission, and only 388 (28.9%) had proximal vessel occlusion. 22 No data are available regarding the severity of deficit, age distribution, or degree of parenchymal infarct of this cohort with largevessel occlusion. It is unlikely that all the large-vessel disease would meet the criteria for intra-arterial therapy. From the 28.9% with large-vessel occlusion in the CT angiography study, it is likely that 10% would be eligible for endovascular therapy, given that in the second described estimating method a small percentage of the screened patients were found eligible. It is likely that the other 18.9% would be excluded for other factors, such as mild clinical deficit, improving deficit, age, and comorbidities. In a different AIS registry, the NIHSS score was Ͻ4 for about 41% of the cohort, between 5 and 9 for 24%, and Ͼ24 for almost 7%, for a total of 72% potentially excluded due to NIHSS score alone. 23 This leaves about 28% with an NIHSS score between 10 and 24. 23 If one-third of those with severe strokes are older than 85 years, then the estimate would be the same as in the Canadian study (18% of all stroke admissions), assuming every patient meets all other criteria for endovascular therapy, including arrival within time and no other medical exclusions. However, in this registry, only 0.7% of the patients were treated with intra-arterial thrombolysis within 6 hours, and 21% were treated with IV fibrinolytic therapy.
In our hospital (Medical College of Wisconsin/Froedtert Hospital), of the 625 cases of ischemic stroke, the number treated last year with endovascular therapy was 64, or 10.2% of all stroke admissions. Two of the patients we did not treat were randomized to receive IV thrombolytic therapy only in the IMS III trial. In this supplement, Zahuranec et al. review the work done by several stroke groups on AIS patients' arrival at the emergency department and their median stroke scale scores, concluding that only 5% to 13% of patients may be eligible for intra-arterial thrombolytic therapy. This would translate to 34,000 to 87,750 patients annually, on the basis of a total of 675,000 AIS patients. Table 2 summarizes the estimates of AIS patients who may be eligible for endovascular therapy according to the previously described methods.
Estimating the workforce. The workforce is the number of NIs needed to provide continuous coverage, given a specific demand, within a geographic radius. It is assumed that specialists provide 24/7 coverage and will be able to serve a reasonable geographic radius (approximately 50 miles) that would allow for patient transfer in a timely manner. This number of NIs is dependent on a balance between a sufficient case volume to maintain proficiency and an overwhelming case volume that leads to provider fatigue. Therefore, proficiency criteria are needed to define this balance. Data on the minimum volume of cases required for NIs to maintain competency are lacking.
The mean range estimate of AIS patients eligible for endovascular therapy is 27,000 to 97,000 patients. If we divide the number of projected cases requiring endovascular therapy by the current estimated number of fellowship-trained NIs (800), it would translate to 34 to 121 cases per each NI. This estimate of the annual number of cases per practitioner would be lower (27 to 97) if the number of NIs were closer to 1,000, or even as low as 23 to 81 if the number of NIs were 1,200.
Hospital locations were geocoded in ArcGIS (Esri, Redlands, CA) with use of the Esri Street Map US Street Addresses locator. To generate the maps in the figure, we used ArcGIS as well as geographic boundaries for US states and counties from Esri to calculate 20-, 50-, and 70-mile radius buffers around each hospi-tal location. The figure (B, C, and D) depicts the number of NIs per state and their coverage area; note that most of the densely populated regions of the United States are covered by at least 1 NI within the accessible area, defined above as a 50-mile radius (the maps also indicate the different circles of 50-and 70-mile radii with at least 1, 2, or 3 NIs). The maps illustrate higher density in the more populated areas, which seems to be logical since NIs tend to look for areas where they can maintain their skills in other neurointerventional procedures, which is necessary to perform AIS intervention at a high skill level. Coverage 24/7 with at least 3 NIs providing AIS endovascular therapy at a given center was lagging in many states, as shown in the figure, D. This may be why NIs are getting help from diagnostic neuroradiologists and peripheral/body interventionalists to increase the flexibility in providing 24/7 coverage, which is not accounted for in the maps.
DISCUSSION
No data are available to provide an accurate estimate of the demand and supply for AIS endovascular therapy. Our estimates are based on published data on epidemiologic and endovascular therapy as well as several assumptions, which enabled us to come up with various ranges of AIS cases potentially eligible for such therapy. Based on our estimate and the methods used in this article, between 27,000 and 96,000 AIS patients annually (4% to 14% of all patients with ischemic stroke) may be eligible for AIS endovascular therapy.
Our estimates of potential cases used 3 methods: the first was population-based, the second relied on endovascular therapy clinical trials, and the third used local and regional registries, including our own practice at the Medical College of Wisconsin. The mean estimate is that 4% to 14% of all AIS cases (or 27,000 to 97,000) may be eligible for endovascular therapy. It is less likely to reach the upper limit and may be closer to the midpoint of 50,000, which is close to the estimate obtained by other authors who reported that the number of cases needing AIS endovascular therapy is close to 40,000 annually. 24, 25 If these numbers are true and the number of hospitals in the United States is close to 6,000 (per the American Hospital Association), it would yield a rate of 4 to 16 cases per hospital annually, which may dilute technical experience and lead to less than favorable outcomes.
If we are going to have this maximum number of cases, do we have enough NIs to provide such coverage with 24/7 availability, acceptable training, and accessibility (within a 50-mile radius)? In 2004, a report on the manpower for intra-arterial therapy in the United States estimated that 99% of the US population in 2001 lived within a 200-mile radius of at least 1 of the 385 NIs active at that time. 26 The majority of SVIN roundtable attendees believed that the minimum number of AIS endovascular therapy cases necessary for maintaining skills is 12 per year, or 1 every month, given that interventionalists have ade- Table 1 From AIS interventional studies, estimates of patients enrolled vs screened for AIS endovascular therapy and crude estimates of patients eligible for such therapy quate numbers of diagnostic cerebral angiograms. Training standards vary according to different societies and range from 30 to 100 diagnostic cerebral angiograms. 27, 28 Ideally, as per neurovascular AIS intervention training standards, all NIs should be fellowship-trained. 29 Allowing several operators to perform AIS intervention, merely to provide 24/7 coverage and address the workforce need-with variability in comfort level, extent of training, and background-may deter some neurologists from referring AIS patients for endovascular therapy. How to address the workforce needs if the future demand for AIS endovascular therapy increases remains a controversial question. The size of the NI workforce is influenced by a complex set of factors, including training standards, institutional policies, and individual decisions. Furthermore, maintaining proficiency in highly skilled neurointerventional techniques and clinical decision-making demands a judicious case-volume balance.
This study is limited by the described assumptions and lack of prospective population-based data on AIS endovascular therapy. In particular, demand estimates from clinical trials may be difficult to establish because of the variability in trial inclusion and exclusion criteria. The upper range in our report may be an overestimate, given the data from one European registry with a tertiary centralized care system and 0.7% rate of endovascular therapy, 22 and the low rate of IV alteplase use, which is 2% of eligible patients in most countries and 1% to 8% in the United States and Europe. 30 Another limitation concerns estimating the demand from the incidence data of stroke and reporting the findings as simple percentages, which may not be accurate as these are crude estimates. In addition to the aforementioned limitations, we did not account for the hypothetical increase in demand with an aging population. Moreover, the results of randomized clinical trials may increase or decrease the number of patients eligible for endovascular AIS therapy. The manpower estimate is limited by the significant number of AIS interventions performed by experienced general interventional radiologists. Their exact number is not known, but they may provide an additional workforce that can be maximized if demand increases.
The workforce of skilled NIs is estimated to be adequate to meet the current demands of endovascular AIS therapy. However, these estimates lack largepopulation-based data on endovascular therapy for AIS. Estimating the future demand is challenging due to the dynamic field of acute stroke intervention. The demand for endovascular therapy in patients with AIS will likely increase because of an expanding and aging population and advances in patient selection and device technology. Innovative triage solutions, such as comprehensive stroke center systems similar to a trauma model, may improve safe and effective delivery of endovascular therapy for patients with acute ischemic stroke. However, consideration must be given to the balance between the optimal case volume to provide skillful, high-quality manpower and avoiding fatigue among primary operators.
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